1541 — ImmuneOnco Biopharmaceuticals Shanghai Balance Sheet
0.000.00%
Last trade - 00:00
- HK$4.86bn
- HK$4.94bn
- CNY0.39m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Cash | |||
Short Term Investments | |||
Cash and Short Term Investments | 668 | 635 | 609 |
Net Total Accounts Receivable | |||
Net Total Receivables | 0.034 | 0.991 | 0.948 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 704 | 652 | 687 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 164 | 174 | 159 |
Long Term Notes Receivable | |||
Other Long Term Assets | |||
Total Assets | 893 | 840 | 875 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Current Portion of Long Term Debt / Capital Leases | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 2,478 | 51.7 | 116 |
Capital Lease Obligations | |||
Total Long Term Debt | |||
Total Debt | |||
Total Liabilities | 2,491 | 60.8 | 126 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | -1,598 | 779 | 748 |
Total Liabilities & Shareholders' Equity | 893 | 840 | 875 |
Total Common Shares Outstanding |